A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC

Huang, Meijuan; Gong, Youling; Zhu, Jiang; Qin, Yi; Peng, Feng; Ren, Li; Ding, Zhenyu; Liu, Yongmei; Cai, Chunmei; Wang, Yongsheng; Lü, You

doi:10.1007/s10637-019-00811-6

Cited by 5 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pemetrexed (500 mg/m 2 ) and carboplatin (AUC = 5) were given on day 1 of 21-day cycle. The incidence of hypertension of the cohort which received 500 mg of apatinib per day for 2 weeks and then 1 week off (16.7%) was lower than the other two cohorts which received 500 mg (66.7%) and 700 mg (66.7%) of apatinib per day for 3 weeks respectively ( Huang et al, 2020 ). In the study by Huang M, 2020, patients received oral apatinib combined with intravenous pemetrexed and intravenous carboplatin for 4 cycles.…”

Section: Resultsmentioning

confidence: 95%

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

Chan,

Khatib,

Webley

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: In the last few decades, there has been a rapid development in cancer therapies and improved detection strategies, hence the death rates caused by cancer have decreased. However, it has been reported that cardiovascular disease has become the second leading cause of long-term morbidity and fatality among cancer survivors. Cardiotoxicity from anticancer drugs affects the heart’s function and structure and can occur during any stage of the cancer treatments, which leads to the development of cardiovascular disease.Objectives: To investigate the association between anticancer drugs for non-small cell lung cancer (NSCLC) and cardiotoxicity as to whether: different classes of anticancer drugs demonstrate different cardiotoxicity potentials; different dosages of the same drug in initial treatment affect the degree of cardiotoxicity; and accumulated dosage and/or duration of treatments affect the degree of cardiotoxicity.Methods: This systematic review included studies involving patients over 18 years old with NSCLC and excluded studies in which patients’ treatments involve radiotherapy only. Electronic databases and registers including Cochrane Library, National Cancer Institute (NCI) Database, PubMed, Scopus, Web of Science, ClinicalTrials.gov and the European Union Clinical Trials Register were systematically searched from the earliest available date up until November 2020. A full version protocol of this systematic review (CRD42020191760) had been published on PROSPERO.Results: A total of 1785 records were identified using specific search terms through the databases and registers; 74 eligible studies were included for data extraction. Based on data extracted from the included studies, anticancer drugs for NSCLC that are associated with cardiovascular events include bevacizumab, carboplatin, cisplatin, crizotinib, docetaxel, erlotinib, gemcitabine and paclitaxel. Hypertension was the most reported cardiotoxicity as 30 studies documented this cardiovascular adverse event. Other reported treatment-related cardiotoxicities include arrhythmias, atrial fibrillation, bradycardia, cardiac arrest, cardiac failure, coronary artery disease, heart failure, ischemia, left ventricular dysfunction, myocardial infarction, palpitations, and tachycardia.Conclusion: The findings of this systematic review have provided a better understanding of the possible association between cardiotoxicities and anticancer drugs for NSCLC. Whilst variation is observed across different drug classes, the lack of information available on cardiac monitoring can result in underestimation of this association.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020191760, identifier PROSPERO CRD42020191760.

show abstract

Section: Resultsmentioning

confidence: 95%

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

Chan,

Khatib,

Webley

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Combined mutated EGFR-and fusion ALK-targeted therapeutic strategies are applied in patients with malignancies of different histological types. Initially anti-EGFR/ALK TKIs and monoclonal antibodies were used in patients with advanced NSCLC, including gefitinib, erlotinib, afatinib, apatinib, crizotinib, osimertinib, ceritinib, alectinib, brigatinib, lorlatinib, and alectinib (21)(22)(23)(24)(25)(26). Interestingly, crizotinib was the first Food and Drug Administration-approved ALK inhibitor for utilization in locally advanced or metastatic ALK-positive NSCLC cases, whereas alectinib is a relatively novel, most-promising selective inhibitor (27,28).…”

Section: Discussionmentioning

confidence: 99%

ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity

Chrysovergis¹,

Papanikolaou²,

Mastronikolis³

et al. 2022

In Vivo

View full text Add to dashboard Cite

“…Apatinib is an orally administered RTK inhibitor that targets the vascular endothelial growth factor receptor-2 (VEGFR-2), RET, platelet-derived growth factor-β (PDGFR-β), c-Src and stem cell factor receptor (c-Kit) (4). Apatinib has been used in combination with pemetrexed and carboplatin in non-squamous non-small-cell lung cancer (5) and in combination with docetaxel in lung adenocarcinoma (6). Although apatinib has significant side effects, like hypertension, hand foot syndrome, fatigue and others, at lower doses of 250 mg per day it is well tolerated (6).…”

mentioning

confidence: 99%

Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib

Cecere

Aguilar

Rosell

2019

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

In one of the latest issues of Translational Lung Cancer Research (TLCR), Jiang et al. have reported on the frequent cavitation of lung metastases in metastatic lung and gastric cancer patients following treatment with apatinib. It has been recognized that anti-angiogenic compounds surface among the anti-cancer therapies, inducing lung cavitation. Although lung cavitation was not found to influence PFS and OS in previous studies (1), the study of Man Jiang, directed by Xiaochun Zhang, has shown that apatinib induces cavitation of lung metastases in a significant number of patients treated with apatinib. Detection of cavitation of lung metastases was associated with longer PFS and OS. What is lung cavitation? Cavitary lung diseases have, for a long time, been an object of study and have broad differential diagnoses. The study of Jiang et al. opens the gates for further clarification of this subject. A cavity is defined as a gas-filled space, seen as a lucency or low attenuation area, between a nodule, mass or area of parenchymal consolidation. It also has a clearly defined wall, 4 mm thick (2). Multiple peripheral nodules in variant stages of cavitations could indicate septic emboli, pulmonary Langerhans cell histiocytosis, possible infarction or tumors with hemorrhage. True cavities should be differentiated from cystic disease, emphysema, infected bullae and cystic bronchiectasis. Cavities are relatively frequent in lung cancer, with an incidence of up to 20% in chest CT scans. Pulmonary metastases can also cavitate. In the current study, the lung cavitation was clearly associated with apatinib treatment, since it occurred in a short period of time, less than 12 weeks, according to prior imaging. What is apatinib? Apatinib is a multi-receptor tyrosine kinase (RTK) inhibitor

show abstract

A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC

Cited by 5 publications

References 26 publications

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity

Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib

Contact Info

Product

Resources

About